Oral intoxication of mice with Shiga toxin type 2a (Stx2a) and protection by anti-Stx2a monoclonal antibody 11E10

Infection and Immunity

Volumn 82, Issue 3, 2014, Pages 1213-1221

  Russo, L M ^a   Melton Celsa, A R ^a   Smith, M A ^a   Smith, M J ^a   O'Brien, A D ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; EPITHELIAL CELLS; FEMALE; KIDNEY TUBULES; MICE; MICE, INBRED BALB C; SHIGA TOXIN 2; WATER-ELECTROLYTE BALANCE;

EID: 84894235224     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01264-13     Document Type: Article

References (55)

1. Tilden J, Jr, Young W, McNamara AM, Custer C, Boesel B, Lambert-Fair MA, Majkowski J, Vugia D, Werner SB, Hollingsworth J, Morris JG, Jr. 1996. A new route of transmission for Escherichia coli: infection from dry fermented salami. Am. J. Public Health 86:1142-1145. http://dx .doi.org/10.2105/AJPH.86.8_Pt_1.1142.
2. Scallan E, Hoekstra RM, Angulo FJ, Tauxe RV, Widdowson MA, Roy SL, Jones JL, Griffin PM. 2011. Foodborne illness acquired in the United States-major pathogens. Emerg. Infect. Dis. 17:7-15. http://dx.doi.org /10.3201/eid1701.09-1101p1.
3. Hancock DD, Besser TE, Rice DH, Tarr PI. 1998. Ecology of Escherichia coli O157:H7 in cattle and impact of management practices, p 85-91. In Kaper JB, O'Brien AD (ed), Escherichia coli O157:H7 and other Shiga toxin-producing E. coli strains. American Society for Microbiology, Washington, DC.
4. Painter JA, Hoekstra RM, Ayers T, Tauxe RV, Braden CR, Angulo FJ, Griffin PM. 2013. Attribution of foodborne illnesses, hospitalizations, and deaths to food commodities by using outbreak data, United States, 1998-2008. Emerg. Infect. Dis. 19:407-415. http://dx.doi.org/10.3201 /eid1903.111866.
5. Rangel JM, Sparling PH, Crowe C, Griffin PM, Swerdlow DL. 2005. Epidemiology of Escherichia coli O157:H7 outbreaks, United States, 1982-2002. Emerg. Infect. Dis. 11:603-609. http://dx.doi.org/10.3201 /eid1104.040739.
6. Karmali MA, Petric M, Lim C, Fleming PC, Arbus GS, Lior H. 1985. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J. Infect. Dis. 151:775-782. http://dx.doi.org/10.1093/infdis/151.5.775.
7. Mayer CL, Leibowitz CS, Kurosawa S, Stearns-Kurosawa DJ. 2012. Shiga toxins and the pathophysiology of hemolytic uremic syndrome in humans and animals. Toxins 4:1261-1287. http://dx.doi.org/10.3390 /toxins4111261.
8. Kaplan BS, Cleary TG, Obrig TG. 1990. Recent advances in understanding the pathogenesis of the hemolytic uremic syndromes. Pediatr. Nephrol. 4:276-283. http://dx.doi.org/10.1007/BF00857676.
9. Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI. 2000. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N. Engl. J. Med. 342:1930-1936. http://dx.doi .org/10.1056/NEJM200006293422601.
10. Wen SX, Teel LD, Judge NA, O'Brien AD. 2006. Genetic toxoids of Shiga toxin types 1 and 2 protect mice against homologous but not heterologous toxin challenge. Vaccine 24:1142-1148. http://dx.doi.org/10.1016/j.vaccine.2005.08.094.
11. O'Brien AD, Holmes RK. 1987. Shiga and Shiga-like toxins. Microbiol. Rev. 51:206-220.
12. Melton-Celsa AR, Smith MJ, O'Brien AD. 2005. Shiga toxins: potent poisons, pathogenicity determinants, and pharmacological agents. EcoSal Plus http://dx.doi.org/10.1128/ecosalplus.8.7.8.
13. Endo Y, Tsurugi K, Yutsudo T, Takeda Y, Ogasawara T, Igarashi K.1988. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes.RNAN-glycosidase activity of the toxins. Eur. J. Biochem. 171:45-50.
14. Saxena SK, O'Brien AD, Ackerman EJ. 1989. Shiga toxin, Shiga-like toxin II variant, and ricin are all single-site RNA N-glycosidases of 28 S RNA when microinjected into Xenopus oocytes. J. Biol. Chem. 264:596-601.
15. Obrig TG. 1997. Shiga toxin mode of action in E. coli O157:H7 disease. Front. Biosci. 2:d635-d642.
16. Boerlin P, McEwen SA, Boerlin-Petzold F, Wilson JB, Johnson RP, Gyles CL. 1999. Associations between virulence factors of Shiga toxinproducing Escherichia coli and disease in humans. J. Clin. Microbiol. 37: 497-503.
17. Ostroff SM, Tarr PI, Neill MA, Lewis JH, Hargrett-Bean N, Kobayashi JM. 1989. Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections. J. Infect. Dis. 160: 994-998. http://dx.doi.org/10.1093/infdis/160.6.994.
18. Scotland SM, Willshaw GA, Smith HR, Rowe B. 1987. Properties of strains of Escherichia coli belonging to serogroup O157 with special reference to production of Vero cytotoxins VT1 and VT2. Epidemiol. Infect. 99:613-624. http://dx.doi.org/10.1017/S0950268800066462.
19. Moxley RA, Francis DH. 1998. Overview of animal models, p 249-260. In Kaper JB, O'Brien AD (ed), Escherichia coli O157:H7 and other Shiga toxin-producing E. coli strains. ASM Press, Washington, DC.
20. Melton-Celsa AR, O'Brien AD. 2003. Animal models for STEC-mediated disease. Methods Mol. Med. 73:291-305.
21. Mohawk KL, O'Brien AD. 2011. Mouse models of Escherichia coli O157:H7 infection and Shiga toxin injection. J. Biomed. Biotechnol. 2011:258185. http://dx.doi.org/10.1155/2011/258185.
22. Smith MJ, Melton-Celsa AR, Sinclair JF, Carvalho HM, Robinson CM, O'Brien AD. 2009. Monoclonal antibody 11E10, which neutralizes Shiga toxin type 2 (Stx2), recognizes three regions on the Stx2 A subunit, blocks the enzymatic action of the toxin in vitro, and alters the overall cellular distribution of the toxin. Infect. Immun. 77:2730-2740. http://dx.doi.org /10.1128/IAI.00005-09.
23. Edwards AC, Melton-Celsa AR, Arbuthnott K, Stinson JR, Schmitt CK, Wong HC, O'Brien AD. 1998. Vero cell neutralization and mouse protective efficacy of humanized monoclonal antibodies against Escherichia coli toxins Stx1 and Stx2, p 388-392. In Kaper JB, O'Brien AD (ed), Escherichia coli O157:H7 and other Shiga toxin-producing E. coli strains.ASM Press, Washington, DC.
24. Pai CH, Kelly JK, Meyers GL. 1986. Experimental infection of infant rabbits with verotoxin-producing Escherichia coli. Infect. Immun. 51: 16-23.
25. Ritchie JM, Thorpe CM, Rogers AB, Waldor MK. 2003. Critical roles for stx2, eae, and tir in enterohemorrhagic Escherichia coli-induced diarrhea and intestinal inflammation in infant rabbits. Infect. Immun. 71:7129-7139. http://dx.doi.org/10.1128/IAI.71.12.7129-7139.2003.
26. Rasooly R, Do PM, Griffey SM, Vilches-Moure JG, Friedman M. 2010. Ingested Shiga toxin 2 (Stx2) causes histopathological changes in kidney, spleen, and thymus tissues and mortality in mice. J. Agric. Food Chem. 58:9281-9286. http://dx.doi.org/10.1021/jf101744z.
27. Russo LM, Melton-Celsa AR, Smith MJ, O'Brien AD. 2012. Analysis of chimeric shiga toxins (Stxs) to determine the contribution of individual Stx subunits to cytotoxicity and mouse lethality, abstr D2-3. Abstr. 8th Int. Symp. Shiga Toxin Producing E. coli Infect. VTEC 2012, 6 to 9 May 2012, Amsterdam, The Netherlands.
28. Tesh VL, Samuel JE, Perera LP, Sharefkin JB, O'Brien AD. 1991. Evaluation of the role of Shiga and Shiga-like toxins in mediating direct damage to human vascular endothelial cells. J. Infect. Dis. 164:344-352. http://dx.doi.org/10.1093/infdis/164.2.344.
29. Lindgren SW, Melton AR, O'Brien AD. 1993. Virulence of enterohemorrhagic Escherichia coli O91:H21 clinical isolates in an orally infected mouse model. Infect. Immun. 61:3832-3842.
30. Strockbine NA, Marques LR, Holmes RK, O'Brien AD. 1985. Characterization of monoclonal antibodies against Shiga-like toxin from Escherichia coli. Infect. Immun. 50:695-700.
31. Downes FP, Barrett TJ, Green JH, Aloisio CH, Spika JS, Strockbine NA, Wachsmuth IK. 1988. Affinity purification and characterization of Shigalike toxin II and production of toxin-specific monoclonal antibodies. Infect. Immun. 56:1926-1933.
32. Gentry MK, Dalrymple JM. 1980. Quantitative microtiter cytotoxicity assay for Shigella toxin. J. Clin. Microbiol. 12:361-366.
33. U.S. National Research Council, Committee for the Update of the Guide for the Care and Use of Laboratory Animals, Institute for Laboratory Animal Research. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.
34. Kokai-Kun JF, Melton-Celsa AR, O'Brien AD. 2000. Elastase in intestinal mucus enhances the cytotoxicity of Shiga toxin type 2d. J. Biol. Chem. 275:3713-3721. http://dx.doi.org/10.1074/jbc.275.5.3713.
35. Perera LP, Marques LR, O'Brien AD. 1988. Isolation and characterization of monoclonal antibodies to Shiga-like toxin II of enterohemorrhagic Escherichia coli and use of the monoclonal antibodies in a colony enzymelinked immunosorbent assay. J. Clin. Microbiol. 26:2127-2131.
36. Fulton RJ, Uhr JW, Vitetta ES. 1986. The effect of antibody valency and lysosomotropic amines on the synergy between ricin A chain-and ricin B chain-containing immunotoxins. J. Immunol. 136:3103-3109.
37. Tesh VL, Burris JA, Owens JW, Gordon VM, Wadolkowski EA, O'Brien AD, Samuel JE. 1993. Comparison of the relative toxicities of Shiga-like toxins type I and type II for mice. Infect. Immun. 61:3392-3402.
38. Rutjes NW, Binnington BA, Smith CR, Maloney MD, Lingwood CA.2002. Differential tissue targeting and pathogenesis of verotoxins 1 and 2 in the mouse animal model. Kidney Int. 62:832-845. http://dx.doi.org/10 .1046/j.1523-1755.2002.00502.x.
39. Wadolkowski EA, Sung LM, Burris JA, Samuel JE, O'Brien AD. 1990. Acute renal tubular necrosis and death of mice orally infected with Escherichia coli strains that produce Shiga-like toxin type II. Infect. Immun. 58:3959-3965.
40. Fujii Y, Numata S, Nakamura Y, Honda T, Furukawa K, Urano T, Wiels J, Uchikawa M, Ozaki N, Matsuo S, Sugiura Y, Furukawa K. 2005. Murine glycosyltransferases responsible for the expression of globo-series glycolipids: cDNA structures, mRNA expression, and distribution of their products. Glycobiology 15:1257-1267. http://dx.doi.org/10.1093/glycob /cwj015.
41. Lopez-Novoa JM, Rodriguez-Pena AB, Ortiz A, Martinez-Salgado C, Lopez Hernandez FJ. 2011. Etiopathology of chronic tubular, glomerular and renovascular nephropathies: clinical implications. J. Transl. Med. 9:13. http://dx.doi.org/10.1186/1479-5876-9-13.
42. Tarr PI, Gordon CA, Chandler WL. 2005. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 365:1073-1086. http://dx.doi.org/10.1016/S0140-6736(05)71144-2.
43. Kashiwamura M, Kurohane K, Tanikawa T, Deguchi A, Miyamoto D, Imai Y. 2009. Shiga toxin kills epithelial cells isolated from distal but not proximal part of mouse colon. Biol. Pharm. Bull. 32:1614-1617. http://dx .doi.org/10.1248/bpb.32.1614.
44. Cheng LW, Stanker LH, Henderson TD, II, Lou J, Marks JD. 2009. Antibody protection against botulinum neurotoxin intoxication in mice. Infect. Immun. 77:4305-4313. http://dx.doi.org/10.1128/IAI.00405-09.
45. Stearns-Kurosawa DJ, Collins V, Freeman S, Debord D, Nishikawa K, Oh SY, Leibowitz CS, Kurosawa S. 2011. Rescue from lethal Shiga toxin 2-induced renal failure with a cell-permeable peptide. Pediatr. Nephrol. 26:2031-2039. http://dx.doi.org/10.1007/s00467-011-1913-y.
46. Mohawk KL, Melton-Celsa AR, Zangari T, Carroll EE, O'Brien AD.2010. Pathogenesis of Escherichia coli O157:H7 strain 86-24 following oral infection of BALB/c mice with an intact commensal flora. Microb. Pathog. 48:131-142. http://dx.doi.org/10.1016/j.micpath.2010.01.003.
47. Richardson SE, Karmali MA, Becker LE, Smith CR. 1988. The histopathology of the hemolytic uremic syndrome associated with verocytotoxinproducing Escherichia coli infections. Hum. Pathol. 19:1102-1108. http: //dx.doi.org/10.1016/S0046-8177(88)80093-5.
48. Boyd B, Lingwood C. 1989. Verotoxin receptor glycolipid in human renal tissue. Nephron 51:207-210. http://dx.doi.org/10.1159/000185286.
49. Weeratna RD, Doyle MP. 1991. Detection and production of verotoxin 1 of Escherichia coli O157:H7 in food. Appl. Environ. Microbiol. 57:2951-2955.
50. Rasooly R, Do PM. 2010. Shiga toxin Stx2 is heat-stable and not inactivated by pasteurization. Int. J. Food Microbiol. 136:290-294. http://dx .doi.org/10.1016/j.ijfoodmicro.2009.10.005.
51. Harris SM, Yue WF, Olsen SA, Hu J, Means WJ, McCormick RJ, Du M, Zhu MJ. 2012. Salt at concentrations relevant to meat processing enhances Shiga toxin 2 production in Escherichia coli O157:H7. Int. J. Food Microbiol. 159:186-192. http://dx.doi.org/10.1016/j.ijfoodmicro.2012 .09.007.
52. Mohawk KL, Melton-Celsa AR, Robinson CM, O'Brien AD. 2010. Neutralizing antibodies to Shiga toxin type 2 (Stx2) reduce colonization of mice by Stx2-expressing Escherichia coli O157:H7. Vaccine 28:4777-4785. http://dx.doi.org/10.1016/j.vaccine.2010.04.099.
53. Robinson CM, Sinclair JF, Smith MJ, O'Brien AD. 2006. Shiga toxin of enterohemorrhagic Escherichia coli type O157:H7 promotes intestinal colonization. Proc. Natl. Acad. Sci. U. S. A. 103:9667-9672. http://dx.doi .org/10.1073/pnas.0602359103.
54. Lingwood CA. 1993. Verotoxins and their glycolipid receptors. Adv. Lipid Res. 25:189-211.
55. Lingwood CA. 1996. Role of verotoxin receptors in pathogenesis. Trends Microbiol. 4:147-153. http://dx.doi.org/10.1016/0966-842X(96)10017-2.